News

UCB has released new data on Neupro, at the 14th International Congress of Parkinson’s Disease and Movement Disorders in Buenos Aires, Argentina, Neupro’s clinical data is investigated through

The data indicated that Arikace, delivered once daily for 28 consecutive days followed by 56 days off-treatment for four cycles, demonstrated improvement in lung function that was sustained

The new applications of RNAi technology define opportunities for the advancement of novel vaccines in many human diseases, including infectious disease and cancer. Alnylam is collaborating with the

OXiGENE said that an updated safety and outcome analysis of the Falcon trial has shown that trends towards improved outcomes were observed in response rate, progression-free survival and

According to the Mymetics, in the Phase Ib trial conducted in cooperation with the Swiss Tropical and Public Health Institute (Swiss TPH) and Pevion Biotech, the vaccine was

The technology is expected to be one of the cornerstones of Oncodesign’s integrated drug discovery efforts, together with the in vitro and in vivo translational research capabilities in

Velcade (bortezomib) is a medicine used to treat the blood based cancer known as multiple myeloma. It contains an active substance called Bortezomib and is the first in

Tibco is going to demonstrate a beta version of the product at the 46th Drug Information Association (DIA) Annual Meeting in Washington. Tibco Software said that the Spotfire

The double-blind pivotal study is expected to compare the efficacy and safety of once-daily oral administration of 200 mg of Torezolid Phosphate over six days of treatment to